Biography

Dr. Robinson completed his medical and ophthalmology training at SUNY Upstate Medical Center and is Board-Certified and a Fellow of the American Board of Ophthalmology.  He completed 3 years of post-doctoral training at the National Eye Institute (NEI) in Bethesda, MD in immunology, pharmacology and completed the didactic training in the Clinical Pharmacology Research Associate Program. He continued on the Attending staff at the NEI and participated in clinical trials as the principal investigator. He was one of the first investigators in the country to implant the Vitrasert (ganciclovir) implant for CMV retinitis and the intravitreal cyclosporine (CsA) implant for uveitis in Phase I trials in man.  He developed the technology for the sub-Tenon’s/ suprachoroidal CsA implant while at the NEI.  The bioerodible version of this CsA implant is now used clinically for Equine Recurrent Uveitis, and the non-erodible version is in Phase 3 clinical trials for prevention of corneal graft rejection.  In 2005, Dr. Robinson started in a new position as a Senior Medical Director in Research and Development at Allergan, Inc. in Irvine, CA.  He was involved in the preclinical and clinical development of both the Ozurdex (dexamethasone) implant and Trivaris (triamcinolone injectable) and both have recently been approved by the Food and Drug Administration.  At Allergan, he is a Global Project Team Lead on projects related to ocular drug delivery.  Dr. Robinson has had numerous publications related to ocular pharmacology and has patents/patent pending related to injectable formulations and drug-delivery implants for the eye.

Presentation Description

Advances in Ocular Drug Delivery